P95 First two US patients with lupus nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101

• Richard Furie,
• James Chung,
• Francis Kim,
• Amber Podoll,
• Justin Chou,
• Ranjita Sengupta,
• Ruthee Bayer,
• Jonathan Gutman

Affiliations

Richard Furie

Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA

James Chung

3Kyverna Therapeutics, Emeryville, USA

Francis Kim

Deparment of Medicine, University of Washington, Seattle, Washington, USA

Amber Podoll

1Dept. of Medicine-Renal Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA

Justin Chou

3Kyverna Therapeutics, Emeryville, USA

Ranjita Sengupta

3Kyverna Therapeutics, Emeryville, USA

Ruthee Bayer

4Dept. of Oncology Hematology, Northwell Health, Lake Success, USA

Jonathan Gutman

5Dept. of Medicine-Hematology, University of Colorado Anschutz Medical Campus, Aurora, USA